Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, PLW

Materia, Inc. and Evonik Reach Agreement on Catalyst License


PASADENA, Calif., Oct. 16, 2017 /PRNewswire/ -- Materia, Inc., a world leading supplier of high performance catalysts and advanced polymers, has entered into a license agreement with Evonik Industries, related to olefin metathesis catalysts, following a patent infringement case between the two companies.

 (PRNewsfoto/Materia, Inc.)

Subject to the terms of the agreement, Evonik allows Materia to make and sell the catalysts that are covered by an injunction issued by the court in August of this year. The agreement also permits Materia's customers to use these catalysts in their products.

"We are pleased to enter into this mutually beneficial agreement with Evonik to ensure that Materia's entire Grubbs catalyst portfolio continues to be available to our customers globally," said Materia Chief Executive Officer, Nitin Apte. "This is an important step in the settlement process and we are encouraged to be moving forward."

The license agreement addresses Evonik's United States Patent Numbers 7,378,528, 7,652,145 and 8,153,810 and related U.S. and foreign patents and patent applications.

About Materia, Inc. 

Materia develops and manufactures catalysts and advanced polymers that solve complex problems facing today's chemical, electronic, energy, industrial, pharmaceutical and transportation companies. With applications ranging from pharmaceutical drugs to subsea oil and gas production to structural composites, Materia's Grubbs Catalyst® technology and Proxima® thermoset resins create differentiated value for its customers. For more information visit: http://materia-inc.com

 

SOURCE Materia, Inc.


These press releases may also interest you

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 11:00
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...

at 11:00
MasterControl, a leading provider of quality management and manufacturing execution software for life sciences, announced it has been recognized by the Imapac 2024 Asia-Pacific Biopharma Excellence Awards in the "Best Bioprocessing Supplier:...

at 10:36
Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been...

at 10:33
The report titled "Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global...



News published on and distributed by: